Volume 87 Issue 21 | p. 15 | Concentrates
Issue Date: May 25, 2009

Novartis Will Buy Generics Firm

Department: Business

Novartis has agreed to acquire EBEWE Pharma, an Austria-based producer of generic injectable drugs, for $1.2 billion in cash. The deal will broaden the global market for EBEWE's oncology medicines—Novartis' Sandoz unit is the world's second-largest generics company. EBEWE's product line includes generic versions of key cancer drugs, including paclitaxel, epirubicin, methotrexate, and oxaliplatin. EBEWE's neurological products business is not part of the deal.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment